Floatz logo

LENALIDOMIDE

B-Cell Non-Hodgkin Lymphoma

Shanghai Junshi Bioscience Co., Ltd.Small moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

305 Active assets in the B-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
Odronextamab
University of Birmingham
Phase 3BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
CYTARABINE
Children's Cancer Group, China
Phase 4BBB
Zanubrutinib
The First Affiliated Hospital of Soochow University
Phase 4BBB

View all 50 →

Same molecule, other indications

LENALIDOMIDE is also rated in:

adult T-cell leukemia/lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
plasma cell neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →
T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →